[English] 日本語
![](img/lk-miru.gif)
- EMDB-41249: Structure of AT118-L Nanobody Antagonist in Complex with the Angi... -
+
Open data
-
Basic information
Entry | ![]() | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Title | Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan | ||||||||||||||||||||||||
![]() | Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan | ||||||||||||||||||||||||
![]() |
| ||||||||||||||||||||||||
![]() | ![]() ![]() ![]() | ||||||||||||||||||||||||
Function / homology | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Similarity search - Function | ||||||||||||||||||||||||
Biological species | ![]() ![]() | ||||||||||||||||||||||||
Method | ![]() ![]() | ||||||||||||||||||||||||
![]() | Skiba MA / Kruse AC | ||||||||||||||||||||||||
Funding support | ![]()
| ||||||||||||||||||||||||
![]() | ![]() Title: Antibodies expand the scope of angiotensin receptor pharmacology. Authors: Meredith A Skiba / Sarah M Sterling / Shaun Rawson / Shuhao Zhang / Huixin Xu / Haoran Jiang / Genevieve R Nemeth / Morgan S A Gilman / Joseph D Hurley / Pengxiang Shen / Dean P Staus / ...Authors: Meredith A Skiba / Sarah M Sterling / Shaun Rawson / Shuhao Zhang / Huixin Xu / Haoran Jiang / Genevieve R Nemeth / Morgan S A Gilman / Joseph D Hurley / Pengxiang Shen / Dean P Staus / Jihee Kim / Conor McMahon / Maria K Lehtinen / Howard A Rockman / Patrick Barth / Laura M Wingler / Andrew C Kruse / ![]() ![]() Abstract: G-protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small-molecule research compounds and therapeutic drugs. While most of these ligands bind to ...G-protein-coupled receptors (GPCRs) are key regulators of human physiology and are the targets of many small-molecule research compounds and therapeutic drugs. While most of these ligands bind to their target GPCR with high affinity, selectivity is often limited at the receptor, tissue and cellular levels. Antibodies have the potential to address these limitations but their properties as GPCR ligands remain poorly characterized. Here, using protein engineering, pharmacological assays and structural studies, we develop maternally selective heavy-chain-only antibody ('nanobody') antagonists against the angiotensin II type I receptor and uncover the unusual molecular basis of their receptor antagonism. We further show that our nanobodies can simultaneously bind to angiotensin II type I receptor with specific small-molecule antagonists and demonstrate that ligand selectivity can be readily tuned. Our work illustrates that antibody fragments can exhibit rich and evolvable pharmacology, attesting to their potential as next-generation GPCR modulators. | ||||||||||||||||||||||||
History |
|
-
Structure visualization
Supplemental images |
---|
-
Downloads & links
-EMDB archive
Map data | ![]() | 157 MB | ![]() | |
---|---|---|---|---|
Header (meta data) | ![]() ![]() | 28.6 KB 28.6 KB | Display Display | ![]() |
Images | ![]() | 44 KB | ||
Filedesc metadata | ![]() | 7.1 KB | ||
Others | ![]() ![]() ![]() ![]() ![]() | 154.3 MB 154.3 MB 157 MB 154.2 MB 154.2 MB | ||
Archive directory | ![]() ![]() | HTTPS FTP |
-Related structure data
Related structure data | ![]() 8th4MC ![]() 8th3C C: citing same article ( M: atomic model generated by this map |
---|---|
Similar structure data | Similarity search - Function & homology ![]() |
-
Links
EMDB pages | ![]() ![]() |
---|---|
Related items in Molecule of the Month |
-
Map
File | ![]() | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan | ||||||||||||||||||||
Voxel size | X=Y=Z: 0.83 Å | ||||||||||||||||||||
Density |
| ||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||
Details | EMDB XML:
|
-Supplemental data
-Additional map: Half Map B of Global Map of AT118-L,...
File | emd_41249_additional_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Half Map B of Global Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab, and anti-Fab Nanobody in Complex with Losartan | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Additional map: Half Map A of Global Map of AT118-L,...
File | emd_41249_additional_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Half Map A of Global Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab, and anti-Fab Nanobody in Complex with Losartan | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Additional map: Global Sharpened Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab,...
File | emd_41249_additional_3.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Global Sharpened Map of AT118-L, AT1R-BRIL,BAG2 Anti-BRIL Fab, and anti-Fab Nanobody in Complex with Losartan | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: Half Map B of Locally Refined Sharpened Map...
File | emd_41249_half_map_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Half Map B of Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: Half Map A of Locally Refined Sharpened Map...
File | emd_41249_half_map_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Half Map A of Locally Refined Sharpened Map of AT118-L, AT1R-BRIL and BAG2 Anti-BRIL Fab Variable Domains in Complex with Losartan | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-
Sample components
-Entire : AT118-L Nanobody Antagonist in Complex with the Angiotensin II Ty...
Entire | Name: AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor BRIL Fusion protein, Anti-BRIL Fab, Anti-Fab Nanobody, and Losartan |
---|---|
Components |
|
-Supramolecule #1: AT118-L Nanobody Antagonist in Complex with the Angiotensin II Ty...
Supramolecule | Name: AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor BRIL Fusion protein, Anti-BRIL Fab, Anti-Fab Nanobody, and Losartan type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1-#4 |
---|---|
Source (natural) | Organism: ![]() ![]() |
-Macromolecule #1: Type-1 angiotensin II receptor Soluble cytochrome b562 complex
Macromolecule | Name: Type-1 angiotensin II receptor Soluble cytochrome b562 complex type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() ![]() |
Molecular weight | Theoretical: 49.501059 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: DYKDDDDKIL NSSTEDGIKR IQDDCPKAGR HNYIFVMIPT LYSIIFVVGI FGNSLVVIVI YFYMKLKTVA SVFLLNLALA DLCFLLTLP LWAVYTAMEY RWPFGNYLCK IASASVSFNL YASVFLLTCL SIDRYLAIVH PMKSRLRRTM LVAKVTCIII W LLAGLASL ...String: DYKDDDDKIL NSSTEDGIKR IQDDCPKAGR HNYIFVMIPT LYSIIFVVGI FGNSLVVIVI YFYMKLKTVA SVFLLNLALA DLCFLLTLP LWAVYTAMEY RWPFGNYLCK IASASVSFNL YASVFLLTCL SIDRYLAIVH PMKSRLRRTM LVAKVTCIII W LLAGLASL PAIIHRNVFF IENTNITVCA FHYESQNSTL PIGLGLTKNI LGFLFPFLII LTSYTLIWKA LKKAYDLEDN WE TLNDNLK VIEKADNAAQ VKDALTKMRA AALDAQKATP PKLEDKSPDS PEMKDFRHGF DILVGQIDDA LKLANEGKVK EAQ AAAEQL KTTRNAYIQK YLERARSTLD KLNDDIFKII MAIVLFFFFS WIPHQIFTFL DVLIQLGIIR DCRIADIVDT AMPI TICIA YFNNCLNPLF YGFLGKKFKR YFLQLLKY UniProtKB: Type-1 angiotensin II receptor, Soluble cytochrome b562, Type-1 angiotensin II receptor |
-Macromolecule #2: BAG2 Anti-BRIL Fab Heavy Chain
Macromolecule | Name: BAG2 Anti-BRIL Fab Heavy Chain / type: protein_or_peptide / ID: 2 / Number of copies: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: synthetic construct (others) |
Molecular weight | Theoretical: 24.539314 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: EISEVQLVES GGGLVQPGGS LRLSCAASGF NVVDFSLHWV RQAPGKGLEW VAYISSSSGS TSYADSVKGR FTISADTSKN TAYLQMNSL RAEDTAVYYC ARWGYWPGEP WWKAFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY F PEPVTVSW ...String: EISEVQLVES GGGLVQPGGS LRLSCAASGF NVVDFSLHWV RQAPGKGLEW VAYISSSSGS TSYADSVKGR FTISADTSKN TAYLQMNSL RAEDTAVYYC ARWGYWPGEP WWKAFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY F PEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCD |
-Macromolecule #3: BAG2 Anti-BRIL Fab Light Chain
Macromolecule | Name: BAG2 Anti-BRIL Fab Light Chain / type: protein_or_peptide / ID: 3 / Number of copies: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: synthetic construct (others) |
Molecular weight | Theoretical: 23.541164 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: DIQMTQSPSS LSASVGDRVT ITCRASQSVS SAVAWYQQKP GKAPKLLIYS ASSLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQ QYLYYSLVTF GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN S QESVTEQD ...String: DIQMTQSPSS LSASVGDRVT ITCRASQSVS SAVAWYQQKP GKAPKLLIYS ASSLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQ QYLYYSLVTF GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN S QESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC |
-Macromolecule #4: AT118-L Nanobody
Macromolecule | Name: AT118-L Nanobody / type: protein_or_peptide / ID: 4 / Number of copies: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: synthetic construct (others) |
Molecular weight | Theoretical: 15.345063 KDa |
Recombinant expression | Organism: ![]() ![]() ![]() |
Sequence | String: EVQLVESGGG LVQPGGSLRL SCAASGYIYS RYRMGWYRQA PGKGREFVAA ISGGSSTNYA DSVKGRFTIS RDNSKNTVYL QMNSLRAED TAVYYCAAYK IDSNPRVYWG QGTQVTVSSG KPIPNPLLGL DSTLEHHHHH H |
-Macromolecule #5: [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]ph...
Macromolecule | Name: [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol type: ligand / ID: 5 / Number of copies: 1 / Formula: LSN |
---|---|
Molecular weight | Theoretical: 422.911 Da |
Chemical component information | ![]() ChemComp-LSN: |
-Experimental details
-Structure determination
Method | ![]() |
---|---|
![]() | ![]() |
Aggregation state | particle |
-
Sample preparation
Concentration | 7 mg/mL |
---|---|
Buffer | pH: 7.4 Details: 20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% GDN, 0.005% CHS |
Grid | Model: UltrAuFoil R1.2/1.3 / Material: GOLD / Mesh: 300 / Pretreatment - Type: GLOW DISCHARGE |
Vitrification | Cryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 293 K / Instrument: FEI VITROBOT MARK IV |
-
Electron microscopy
Microscope | FEI TITAN KRIOS |
---|---|
Electron beam | Acceleration voltage: 300 kV / Electron source: ![]() |
Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD![]() |
Sample stage | Specimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER |
Software | Name: SerialEM (ver. 4.0.5) |
Image recording | Film or detector model: GATAN K3 BIOQUANTUM (6k x 4k) / Average electron dose: 64.1 e/Å2 |
Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
-
Image processing
Particle selection | Number selected: 405950 |
---|---|
Startup model | Type of model: OTHER / Details: Ab Initio Model |
Initial angle assignment | Type: RANDOM ASSIGNMENT / Software - Name: cryoSPARC (ver. 3) |
Final angle assignment | Type: MAXIMUM LIKELIHOOD / Software - Name: cryoSPARC (ver. 3) |
Final reconstruction | Applied symmetry - Point group: C1 (asymmetric) / Resolution.type: BY AUTHOR / Resolution: 3.3 Å / Resolution method: FSC 0.143 CUT-OFF / Software - Name: cryoSPARC (ver. 3) / Number images used: 238621 |